論文 - 詳細
| RRC ID | 61024 |
|---|---|
| 著者 | Wang Y, Liu Y, Zhou C, Wang C, Zhang N, Cao D, Li Q, Wang Z. |
| タイトル | An AKR1C3-specific prodrug with potent anti-tumor activities against T-ALL. |
| ジャーナル | Leuk Lymphoma |
| Abstract |
AKR1C3 overexpression has been reported in various types of cancers, including T-ALL. AST-006 (TH-3424), an AKR1C3-specific prodrug, was reported recently to have potent cytotoxicity against liver cancer cells overexpressing AKR1C3 and T-ALL. In this study, AST-006 demonstrated potent anti-tumor activity against different T-ALL cell lines in vitro and in vivo, including patient-derived xenograft (PDX) model. AST-006 also exhibited minimal cytotoxicity against primary human T-cells in vitro and lymphocytes in cynomolgus monkeys in vivo, indicating that AST-006 is a promising therapeutic for T-ALL. |
| 巻・号 | 61(7) |
| ページ | 1660-1668 |
| 公開日 | 2020-7-1 |
| DOI | 10.1080/10428194.2020.1728746 |
| PMID | 32091283 |
| MeSH | Aldo-Keto Reductase Family 1 Member C3 Antineoplastic Agents, Alkylating Cell Line, Tumor Humans Precursor T-Cell Lymphoblastic Leukemia-Lymphoma* Prodrugs* / pharmacology Xenograft Model Antitumor Assays |
| IF | 2.969 |
| オルトメトリクス指標 |
オルトメトリクス指標項目
|
| 最多言及媒体 | Patent(IFI CLAIMS) |
| 各媒体での言及数の合計 | 5 |
| 過去6か月間でのオルトメトリクス指標の変動値 | 0.0 |
| リソース情報 | |
| ヒト・動物細胞 | ATN-1(RCB1440) |